New cancer drug DXP-106 enters early human testing

NCT ID NCT07532018

Recruiting now Disease control Sponsor: Singlomics Biopharmaceuticals Zhuhai Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new drug called DXP-106 in 54 people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if DXP-106 works better when given alone or with chemotherapy. Participants receive the drug by infusion, and researchers monitor side effects and tumor response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER SOLID TUMOR

Contacts and locations

Locations

Harbin Medical University Cancer Hospital
NOT_YET_RECRUITING

Harbin, Heilongjiang, 150081, China
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
NOT_YET_RECRUITING

Hangzhou, Zhejiang, 310009, China
Zhongshan Hospital, Fudan University
RECRUITING

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.